This study determined the effects of cumulative exposure to painful needle procedures and sucrose analgesia on the development of remote hyperalgesia in newborn infants, defined as an increase in response to a normally painful stimulus at a site distal from the site of injury. One-hundred and twenty healthy newborns and 120 healthy newborn infants of diabetic mothers equally randomized to sucrose analgesia or placebo prior to all needle procedures in the first two days after birth were divided into two exposure groups according to number of needle procedures they had undergone [high (P5) or low (64)] using the median cut-off technique. Compared to the low exposure group, infants in the high exposure group had a higher pain response during a subsequent venipuncture distal to the site of previous injury, assessed by the Premature Infant Pain Profile (PIPP) [7.1 vs. 8.4; p = 0.012] and Visual Analog Scale (VAS) [2.5 cm vs. 3.2 cm; p = 0.047], and a trend for longer cry duration [25.7 s vs. 33.8 s; p = 0.171]. PIPP scores did not differ during a routine diaper change, suggesting a nociceptive specific mechanism for the remote hyperalgesia to venipuncture. Sucrose reduced PIPP, VAS, and cry duration scores during venipuncture, but did not prevent hyperalgesia (p > 0.05). There was a preponderance of infants of diabetic mothers in the high exposure group; however, the analysis did not demonstrate this to be a confounding factor. In conclusion, sucrose analgesia for repeated painful procedures in the first day of life does not prevent development of remote hyperalgesia in newborns.
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Introduction
Newborn infants are subjected to procedural pain as part of routine medical care. Untreated procedural pain can lead to profound adverse effects. We previously demonstrated that newborn infants born to mothers with diabetes and who underwent repeated heel lances in the first 24-36 h of life exhibited hyperalgesia (an increased response to a stimulus which is normally painful) during a subsequent venipuncture compared to normal infants who had not undergone repeated painful procedures [25] . Other studies have demonstrated that injury during infancy has local and global consequences on sensory processing that can be observed years later [16] .
A significant percentage of newborn infants are subjected to repeated procedural pain. Infants of diabetic mothers (IDMs) alone constitute approximately 5% of live births [18] . An additional 10-15% of newborns require prolonged hospitalization after delivery for medical reasons including prematurity, congenital anomalies, sepsis, hyperbilirubinemia and feeding difficulties [13] . Individually, these infants may be exposed to up to hundreds of painful procedures [9] . Reducing the burden of pain from medical procedures in newborn infants is therefore clinically important [4, 5] .
Sucrose (table sugar) is a naturally occurring sweetener with analgesic effects in young infants. Although not fully understood, the mechanism of action is postulated to involve activation of the endogenous opioid system through taste [7] . This is supported by the presence of opioid receptors on the tongue and animal studies demonstrating opioid-antagonist reversible analgesia during noxious stimulation [19] . Moreover, chronic consumption of sweeteners has been shown to negate the analgesic effects of opioids [14] .
Sucrose has been promoted for analgesia in clinical practice guidelines and consensus statements based on systematic reviews demonstrating its efficacy for common medical procedures such as heel lance and venipuncture [2, 3, 8, 21, 22] . There is a lack of data, however, on the effects of repeated doses. Specifically, it is unclear PAIN Ò 144 (2009) 
